Selective muscarinic receptor antagonists for airway diseases
- PMID: 11712743
- DOI: 10.1016/s1471-4892(01)00040-6
Selective muscarinic receptor antagonists for airway diseases
Abstract
Airway tone and airway hyperreactivity are mediated by the parasympathetic nerves that release acetylcholine onto muscarinic receptors (M1-M5). Stimulation of M1 and M3 muscarinic receptors causes bronchoconstriction. The M1 muscarinic receptor is excitatory, and facilitates neuronal transmission at the parasympathetic ganglion. The M2 receptor is an inhibitory prejunctional autoreceptor. The discovery of discrete muscarinic receptor subtypes prompted development of selective muscarinic receptor antagonists. Selective M3 receptor antagonists and antagonists selective for M1 and M3 receptors have recently entered clinical trials and offer much promise for the treatment of airways diseases.
Similar articles
-
Muscarinic acetylcholine receptors and airway diseases.Pharmacol Ther. 2003 Apr;98(1):59-69. doi: 10.1016/s0163-7258(03)00004-4. Pharmacol Ther. 2003. PMID: 12667888 Review.
-
Ozone-induced airway hyperresponsiveness and loss of neuronal M2 muscarinic receptor function.J Appl Physiol (1985). 1994 Mar;76(3):1088-97. doi: 10.1152/jappl.1994.76.3.1088. J Appl Physiol (1985). 1994. PMID: 8005850
-
Treatment of disorders characterized by reversible airway obstruction in childhood: are anti-cholinergic agents the answer?Curr Pharm Des. 2012;18(21):3061-85. doi: 10.2174/1381612811209023061. Curr Pharm Des. 2012. PMID: 22564300 Review.
-
A mechanism for rapacuronium-induced bronchospasm: M2 muscarinic receptor antagonism.Anesthesiology. 2003 Apr;98(4):906-11. doi: 10.1097/00000542-200304000-00017. Anesthesiology. 2003. PMID: 12657852
-
Prejunctional muscarinic receptors on cholinergic nerves in guinea pig airways are of the M2 subtype.Eur J Pharmacol. 1991 Jan 25;193(1):117-9. doi: 10.1016/0014-2999(91)90209-9. Eur J Pharmacol. 1991. PMID: 2050188
Cited by
-
Safety, tolerability and pharmacokinetics and pharmacodynamics of inhaled once-daily umeclidinium in healthy adults deficient in CYP2D6 activity: a double-blind, randomized clinical trial.Clin Drug Investig. 2013 Sep;33(9):653-64. doi: 10.1007/s40261-013-0109-6. Clin Drug Investig. 2013. PMID: 23881566 Clinical Trial.
-
Therapy for chronic obstructive pulmonary disease in the 21st century.Drugs. 2003;63(19):1973-98. doi: 10.2165/00003495-200363190-00002. Drugs. 2003. PMID: 12962514 Review.
-
Gestational exposures to organophosphorus insecticides: From acute poisoning to developmental neurotoxicity.Neuropharmacology. 2020 Dec 1;180:108271. doi: 10.1016/j.neuropharm.2020.108271. Epub 2020 Aug 16. Neuropharmacology. 2020. PMID: 32814088 Free PMC article. Review.
-
Network pharmacology-based analysis of Zukamu granules for the treatment of COVID-19.Eur J Integr Med. 2021 Feb;42:101282. doi: 10.1016/j.eujim.2020.101282. Epub 2021 Jan 2. Eur J Integr Med. 2021. PMID: 33425074 Free PMC article.
-
In Vivo Pharmacological Testing of Herbal Drugs for Anti-Allergic and Anti-Asthmatic Properties.J Pharm Bioallied Sci. 2021 Oct-Dec;13(4):380-386. doi: 10.4103/jpbs.jpbs_454_21. Epub 2022 Mar 4. J Pharm Bioallied Sci. 2021. PMID: 35399803 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources